Clinical Analysis of Dual Antiplatelet Therapy Based on CYP2C19 Gene Rapid Test in SAO Patients within 72 Hours
10.11969/j.issn.1673-548X.2025.09.024
- VernacularTitle:72h内SAO患者基于CYP2C19基因快检双重抗血小板治疗的临床分析
- Author:
Hui NI
1
;
Guo-fang CHEN
;
Weiwei LIU
Author Information
1. 221009 徐州医科大学徐州临床学院
- Publication Type:Journal Article
- Keywords:
Small artery occlusion;
CYP2C19;
Clopidogrel;
Dual antiplatelet therapy;
Treatment time window;
Rapid genetic testing
- From:
Journal of Medical Research
2025;54(9):142-146,163
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of dual antiplatelet therapy within 72hours of onset in patients with small artery occlusion(SAO)who do not carry the cytochrome P450 2C19(CYP2C19)loss-of-function(LOF)allele,under the precise guidance of rapid testing for the CYP2C19gene.Methods A retrospective study was conducted to collect patients with stroke of SAO who presented within 72hours of onset and did not carry the CYP2C19 LOF allele,attending the Department of Neurology,Xuzhou Central Hospital between January and December 2023.Patients were divided into two groups:the control group and the experimental group,the control group received aspirin monotherapy,and the experimental group received dual antiplatelet therapy with aspirin and clopidogrel.Baseline characteristics of both groups were collected,and the modified Rankin scale(mRS)scores and National Institutes of Health Stroke Scale(NIHSS)scores were recorded on the 1st,7th,21st and 90th days of treatment.Additionally,the occurrence of adverse e-vents was documented.The primary efficacy outcome was the incidence of new stroke within 90 days,while the primary safety outcome was the occurrence of moderate-to-severe bleeding within 90days.Results A total of 130 patients were enrolled in the study,with 61 patients in the control group,and 69 patients in the experimental group.Within the experimental group,patients with stroke onset within 24 hours accounted for 11.6％,those with onset between 24 and 48 hours accounted for 47.8％,and those with onset between 48 and 72 hours accounted for 40.6％.There were no statistically significant differences in baseline characteristics between the two groups(P＞0.05).Regarding new strokes within 90days,there were 9 cases(14.8％)in the control group,and 3 cases(4.3％)in the experimen-tal group,with a statistically significant difference(x2=4.185,P＜0.05).For moderate-to-severe bleeding within 90days,there were 0 cases in the control group,and 1 case(1.4％)in the experimental group,there was no statistically significant difference between the two groups(P＞0.05).Conclusion For patients with stroke of SAO who are non-carriers of CYP2C19 LOF allele and have onset within 72 hours,dual antiplatelet therapy with aspirin combined with clopidogrel can effectively reduce the recurrence of stroke.Addition-ally,the two drugs demonstrate consistent safety profiles,with no observed increase in adverse events such as bleeding associated with the combination therapy.
